Browse
Recent Submissions
Now showing 1 - 4 of 4
- ItemAdvancements in Myeloid Leukemia Treatment: A Comprehensive Update(Journal of Biological Sciences, 2023) Hauwa Ali Buhari; Salisu, Muhammad; Emmanuel Ifeanyi ObeaguThis comprehensive update explores the recent advancements in the treatment landscape of myeloid leukemia. Myeloid leukemia, a heterogeneous group of hematological malignancies, poses significant challenges in clinical management. This review highlights the latest therapeutic approaches, including targeted therapies, immunotherapies, and emerging treatment modalities. It discusses the impact of precision medicine, novel drug developments, and the evolving role of immunotherapy in managing myeloid leukemia. Furthermore, the abstract outlines current research trends, challenges, and future prospects, aiming to provide a concise overview for healthcare professionals and researchers involved in leukemia management.
- ItemBenign Prostatic Hyperplasia: A Review(EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH, 2023) Emmanuel Ifeanyi Obeagu; Esther U. Alum; Getrude Uzoma Obeagu; Okechukwu Paul-Chima UgwuBenign Prostatic Hyperplasia (BPH) is a noncancerous increase in size of the prostate gland. The symptoms of BPH are mostly lower urinary tract symptoms and these include waking up to urinate at night, urgency, frequency, incontinence of urine and inability to empty the bladder completely and weak urine stream. Nocturia in particular has been found to have negative effect on quality of sleep, energy or vitality. Men realizes they have prostate enlargement when they start experiencing lower urinary tract symptoms. Several new biomarkers for individuals with raised PSA concentrations or those diagnosed with prostate cancer are likely to identify individuals who can be spared aggressive treatment.
- ItemAbnormal Lipid Profile Level in Neonates and Possible Development of Atherosclerosis in Adulthood: Mini Review(International Digital Organization for Scientific Research, 2024) Mathias Abiodun Emokpae; Timothy God-Giveth Olusegun; Oluwasina Moses Egbeyemi; Emmanuel Ifeanyi ObeaguThe lipid profile during the neonatal period plays a pivotal role in determining the future risk of atherosclerosis and cardiovascular diseases in adulthood. Abnormal lipid levels in neonates have been associated with an increased propensity for the development of atherosclerosis later in life. This review aims to explore the significance of abnormal lipid profiles in neonates and their potential implications for the development of atherosclerosis in adulthood. The discussion encompasses the mechanisms underlying lipid metabolism in early life, the impact of various factors on lipid levels in neonates, and the long-term consequences of abnormal lipid profiles. Understanding the relationship between neonatal lipid profiles and the risk of atherosclerosis in adulthood is crucial for developing preventive strategies and interventions aimed at reducing the burden of cardiovascular diseases in later life. This review synthesizes idea from existing literature to provide insights into the importance of early lipid assessment and its implications for long-term cardiovascular health.
- ItemAn Insight on Acute Myeloid Leukemia: Pediatric Perspective(International Journal of Innovative and Applied Research, 2022) Emmanuel Ifeanyi Obeagu; Keerthana GnanavelAcute leukemia is the most common childhood malignancy, accounting for nearly 35% of all childhood cancers. Acute myeloid leukemia (AML) accounts for 15-20% of childhood acute leukemias. The majority of AML cases are de novo, but a minority may present as secondary malignancies. AML is a highly heterogeneous disease, the diagnosis of which involves morphology, immunophenotyping, cytochemistry, and diagnostic analyzes involving leukemic blasts derived from peripheral blood or bone marrow exhibiting cytogenic and molecular characteristics. Includes combinations. By identifying recurrent genetic mutations, it is now possible to improve individual prognosis and guide treatment management. Pediatric acute myeloid leukemia (AML) is a heterogeneous disease that requires a multifaceted therapeutic approach. Although the outcomes of low-risk AML have improved significantly over the past decades, high-risk AML continues to be associated with poor prognosis. Recent advances in molecular diagnostics, risk stratification, and supportive care have helped improve outcomes in childhood AML.